Impella 2.5 Patient Procedure at Mount Sinai Medical Center Featuring New Product Enhancements: Webcast Available

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the webcast of a Impella^® 2.5 procedure featuring new product enhancements at Mount Sinai Medical Center. The webcast is now available and archived on the ABIOMED website (www.abiomed.com).

The webcast was broadcasted live from Mount Sinai Medical Center on January 19, 2010 and presents a successful high-risk percutaneous coronary intervention (PCI) case with Impella 2.5 support, performed by Samir Sharma, M.D., director of the catheterization lab (cath lab) and interventions, and Annapoorna Kini, M.D., associate professor of the cath lab at Mount Sinai Medical Center.

The patient was a 58-year-old male with severe calcific multivessel and left main disease with severe LV dysfunction (LVEF of 25%). A normal LVEF typically ranges from 60 – 66 percent. Impella 2.5 was inserted to maintain left ventricular support and provide hemodynamic stability. "The next generation Impella 2.5 is now a minute preparing. In the past it used to be 10 to 15 minutes,” states Dr. Kini during the live webcast. "In a situation of emergency or cardiogenic shock, the physician can do it quickly.”

"Mount Sinai Medical Center is known for exceptional outcomes and their ability to treat complex patients,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "The next generation Impella 2.5 provides top institutions with excellent hemodynamic support in these complex cases, and has been improved for the urgent care setting.”

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing, regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and the most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Abiomed, Impella and the Abiomed logo are all trademarks of Abiomed.